At the 2014 Transcatheter Cardiovascular Therapeutics (TCT) meeting (13–17 September, Washington, USA), Osprey Medical introduced its enhanced contrast-monitoring technology. The enhanced system, called the Avert Plus, was selected by a team of independent cardiologists from a large list of new technology applicants to be presented at an Emerging Innovative Cardiovascular Technology session during the TCT meeting.
According to a press release, this selection enabled Osprey to highlight its Avert System to physicians attending one of the world’s largest gatherings of cardiologists. The meeting hosts around 12,000 attendees with over 6,000 international medical professionals in the fields of interventional cardiology and vascular medicine.
The press release reports that the Avert Plus is a new technology that features a disposable smart syringe and reusable LCD monitor. The proprietary system offers several key benefits:
• Monitors and displays the calculation of maximum dye dose levels to be used in a patient based on their kidney function before they undergo a procedure.
• Automatically keeps real-time track of the amount of dye being used and the amount diverted by the Avert system upon injection.
• Allows for a more accurate method of recording the dose delivered to the patient.
The Avert Plus provides a simple way for doctors and hospitals to readily comply with new dosage recording guidelines that were recently issued by the US cardiology community to improve the quality of care following coronary procedures such as stenting or angioplasty.
Osprey’s President and CEO, Mike McCormick comments: “The selection of Avert Plus as one of this year’s ‘TCT Innovation Breakthroughs’ is an honour for Osprey, which we believe demonstrates the physician community’s confidence that our Avert system is a significant technology.”
Avert Plus has already received European CE Mark approval and US FDA clearance is pending.
